Press releases

31
May 2023
20:18 E.S.T.

Cellectis Publishes an Article in Cancer Immunology Research Demonstrating Preclinical Evidence of UCART20x22 Product Candidate to Target a Broad Spectrum of Patients with B-cell Malignancies

Read more
24
May 2023
23:05 E.S.T.

Cellectis’ Annual Shareholders General Meeting to be Held on June 27, 2023

Read more
17
May 2023
18:00 E.S.T.

Cellectis Presents Clinical Data on AMELI-01 and Preclinical Data on Multiplex Engineering for Superior Generation of CAR T-cells at ASGCT 2023

Read more
12
May 2023
23:12 E.S.T.

Cellectis Publishes Article in Frontiers in Immunology Unveiling Pre-Clinical Data on a Novel Treatment Paradigm for Successful CAR T Immunotherapy Against Stroma-rich Solid Tumors

Read more
11
May 2023
12:37 E.S.T.

Cellectis Announces Poster Presentation on BALLI-01 at the European Hematology Association (EHA) 2023

Read more
4
May 2023
18:49 E.S.T.

Cellectis Provides Business Update and Reports Financial Results for First Quarter 2023

Read more
2
May 2023
16:05 E.S.T.

Cellectis Announces Oral Presentation on AMELI-01 and Poster Presentation on Multiplex Engineering for Superior Generation of CAR T-cells at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

Read more
27
Apr 2023
14:01 E.S.T.

Cellectis to Report First Quarter 2023 Financial Results on May 4, 2023

Read more
24
Apr 2023
15:39 E.S.T.

Cellectis Implements CLLS52 for the First Time in the Clinic with Sanofi’s Alemtuzumab

Read more
17
Apr 2023
06:00 E.S.T.

Cellectis Presents Preclinical Data on TALEN®-edited MUC1 CAR T-cells to Enhance Efficacy in Targeting Triple Negative Breast Cancer at the American Association for Cancer Research (AACR) Annual Meeting

Read more

Press contacts

For more information on any story, or for press enquiries, get in touch with our communication team

CONTACT US